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Early studies by Lancefield on the immunochemical character of the type-specific antigens 
of group B Streptococcus utilized hot hydrochloric acid (HC1) treatment of whole bacteria for 
extraction of these polysaccharides (1, 2). The HCl-extracted antigens have been shown to be 
of low molecular size, immunologically incomplete, and to consist of galactose, glucosamine, 
and glucose in a  molar ratio of 2:1:1, respectively, (3, 4). 1 Extraction of cells by more gentle 
techniques such as washing with neutral buffer solutions allows  isolation of more complete, 
high molecular weight native polysaccharides which contain in addition to these three mono- 
saccharides a terminal acid-labile determinant, sialic acid (5, 6). 1 The molar ratio of sugars in 
the repeating unit of this native polysaccharide is 2:1:1:1, galactose, glucose, glucosamine, and 
sialic  acid,  respectively.  Acid  treatment  of  these  large  molecular size  antigens  results  in 
degradation to core fragments which are immunochemically identical to the HCl-extracted 
polysaccharides and contain no sialic acid (6). 
It has been our hypothesis that investigation of human immunity to the group B Streptococcus 
should employ purified polysaceharides from the bacterial cell surface or capsule which exist in 
native form (6). These native antigens would be desirable for study since, theoretically, they 
most closely resemble those which the infected host recognizes immunoiogically. 
Our studies  have  demonstrated a  significant association between  low  concentrations of 
maternal antibody directed against the native type III polysaccharide and risk for infant disease 
due to type III, group B streptococci (7). Furthermore, development of anti-native III antibody 
results during recovery from natural infection or after immunization of adults with purified 
native type III polysaccharide (8, 9). 
Although it appeared that antibody to native type III polysaccharide was of great importance 
in our understanding of human immunity to  type  III strains of group  B Streptococcus, the 
relationship between this antibody and that to the core or HCI antigens has not been studied. 
Recently, Wilkinson has reported that high levels of antibody to acid-extracted antigens (hot 
hydrochloric acid or cold trichloracetic acid) exist in acute sera of infants infected with group 
B streptococci (10). These data made clear the necessity for experiments to assess the relative 
importance of antibody to undegraded native sialic acid-containing polysaccharide and anti- 
body to the core antigens which lack these acid labile determinants. 
Unfortunately, experiments aimed at directly determining the relative importance 
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in human  immunity of antibody to these terminal acid-labile constituents or to the 
core structure have not been feasible because of the very small molecular size of the 
hot  HCl-extracted antigen and  its likely nonimmunogenicity  in  humans.  However, 
the  findings  of Fischer  et  al.  (11)  that  the  type  XIV  capsular  polysaccharide  of 
Streptococcus  pneumoniae  cross-reacted immunologically with  the  core  HCI  antigen  of 
type III group B Streptococcus,  in conjunction with our own analysis of the type III core 
antigen  showing  chemical  similarity  to  Lindberg's  et  al.  (12)  description  of  the 
pneumococcal XIV capsule  a suggested that  antibody to core type III antigen might 
be induced by immunization of adults with pneumococcal type XIV polysaccharide. 
Studies were performed to determine the biological relevance of antibody directed 
against  native  and  core  type  III  antigen  in  human  infection  as  well  as  in  adult 
volunteers  immunized  with  native  type  III group  B  streptococcal  and  multivalent 
pneumococcal polysaccharide vaccines (9). 
Materials  and  Methods 
Bacterial  Strains.  Prototype strains  of group  B  Streptococcus representing each  of the  five 
serotypes and the group B variant strain (devoid of type-specific antigen) were kindly supplied 
by Dr. Rebecca Lancefield, The Rockefeller University. These strains are designated 090 (type 
Ia), H36B  (type Ib), A909 (type Ic), 18RS21  (type II), D136c (type III), and 090R  (group B); 
in  addition, strains M732  and  M735  (type III) were  isolated from  infants with  meningitis. 
Lyophilized strains were  rehydrated with  Todd-Hewitt broth  (Difco Laboratories, Detroit, 
Mich.) and incubated overnight at 37°C in 1-ml portions of Todd-Hewitt broth. 
Preparation of Rabbit  Antisera.  New Zealand white rabbits were immunized with formalin- 
killed whole cell vaccines of the  prototype strains of group  B  Streptococcus according to  the 
method of McCarty and  Lancefield (13).  For type Ic-specific antiserum to strain A909,  the 
method of Wilkinson and Eagon was used (14). All rabbit sera had 1:10,000  merthiolate added, 
and were stored at 4°C.  Hyperimmune rabbit antisera to type XIV S. pneumoniae was kindly 
supplied by Dr. Michael Grizzard, Channing Laboratory, Boston, Mass. and was prepared by 
the New York State Department of Health. 
Human Sera.  Acute and convalescent sera from  11  patients with type III group B strepto- 
coccal infection were selected from our collection of patient sera and were chosen because of the 
availability of serum from the mothers of these same infants at the time of infant  infection. 
These women, like the great majority of mothers of infected infants, had low antibody levels to 
native type III antigen (8). 
The sera of 19 randomly selected normal women collected at delivery and cord sera from 
their healthy infants were obtained for antibody studies. None of these women were type III 
group B streptococcal vaginal carriers. 
In another group of 12 adult volunteers selected for low levels of serum antibody to native 
type III antigens, preimmunization serum specimens were collected, and written consent was 
given  before their  immunization  with  multivalent  pneumonococcal  polysaccharide vaccine 
(Pneumovax, Merck, Sharp, & Dohme Research Laboratories, West Point, Pa., Lot no. 2871W) 
containing pneumococcal XIV polysaccharide antigen. Postimmunization sera were obtained 
from these subjects 2 wk after immunization. Subjects were matched according to preimmun- 
ization antibody level as determined by a radioactive antigen-binding assay (7, 8), age and sex, 
with volunteers receiving type III group B streptococcal vaccines who  have been previously 
reported (9). Adults with low levels of antibody to the native polysaccharide were chosen for 
study because this has been shown to be a risk factor for development of neonatal disease (7, 8). 
Sera  from  selected  volunteers  who  were  immunized  with  type  III  group  B  streptococcal 
polysaccharides extracted by neutral buffer ethylenediamine tetra-acetic acid (EDTA)  solution 
or cold trichloroacetic acid (TCA) methods were also studied (9,  15). These sera were selected 
for study because they contained opsonophagocytic antibodies as determined by the method of 
Baltimore et al. (16) 2 wk after immunization. 
2 Abbreviations used in  this paper: cfu, colony-forming units;  EDTA,  ethylenediamine  tetraacetic  acid; 
RABA, radioactive antigen-binding  assay; TCA, trichloroacetic acid. D.  L.  KASPER  ET  AL.  329 
Preparation of Antigens.  Native  (EDTA-extraeted)  and  TCA-extracted type III,  group  B 
streptococcal polysaccharide antigens were isolated from strain M732  by methods described 
previously (6,  15). Type XIV pneumococcal polysaceharide was obtained from Dr. Grizzard 
and came from the Bureau of Biologies, Food, and Drug Administration (Eli Lilly and Co., 
Indianapolis, Ind., Lot no. 812430, Kd =  0.21  Sepharose 4B, information kindly supplied by 
Dr. John B. Robbins, Bureau of Biologies, Food and Drug Administration, Bethesda, Md.). 
The core type III specific polysaccharide of group B Streptococcus was extracted from strain 
M732.  This strain was grown in Todd-Hewitt broth and the organisms pelleted by centrifu- 
gation. The pelleted bacteria were suspended in 0.2 N HCI and boiled for 10 min according to 
the method of Lancefield (1). Debris was removed by eentrifugation at  10,000 g for 15 min at 
4°C. The supernate was then neutralized with NaOH to pH 7.0, fractionated with 30% alcohol, 
and the precipitate discarded. A crude polysaccharide extract was then precipitated from the 
supernatant with  1.5 vol of alcohol, and after centrifugation, this precipitate was saved. The 
supernate was then adjusted to 80% alcohol, centrifuged, and the precipitate was dissolved in 
0.05  M  Tris (Trishydroxymethylaminomethane) buffer, pH  7.4, and this solution was again 
fractionated with 1.5 vol alcohol. The 1.5 vol alcohol precipitates were combined, and extraction 
with cold 8% TCA for 4 h at 4°C was performed to further remove proteins and nucleic acids 
(17).  After centrifugation at  10,000  g  for  10  min,  the supemate was  neutralized with  1 N 
NaOH. At this stage the supernate, which had both type III and group B serologic reactivity 
in capillary precipitin tests, was chromatographed on 2.6  ×  85 cm column of Sephacryl S-200 
(Pharmacia,  Uppsala,  Sweden)  in  0.05  M  Tris,  pH  7.4.  The  serologically active fractions 
containing type III or group B reactivity (13),  excluding UV absorbable material, which was 
of small molecular size, were combined, concentrated on a PM-30 membrane (Amicon Corp., 
Lexington, Mass.). precipitated with 4 vol of alcohol, and suspended in 0.05  M  Tris, pH 8.4. 
Final purification of that type III core antigen devoid of group B antigen was achieved on a 
column of DEAE-Sephacel (Pharmacia) equilibrated in 0,05  M  Tris pH 8.4.  The Kay of the 
type III core antigen was 0.435  (G-100) corresponding to a  molecular size of 46,000 dahons. 
Immunologically, this antigen formed precipitates only with type III-specific antiserum, and 
not with other type-specific or with group B-specific streptococcal antisera (13). 
Serologic Methods.  Capillary precipitin tests were performed by the method of Lancefield (1) 
and immunodiffusion tests were done in agar gel by the method of Ouchterlony (18). 
The radioactive antigen-binding assay (RABA) was performed as previously described by 
using [nH]labeled native type III polysaccharide as the antigen (7, 8). A similar assay employing 
intrinsically [3H]labeled core type III polysaccharide antigen was designed. 
For preparation of the intrinsically labeled core antigen, strain M732 was grown in Todd- 
Hewitt broth supplemented with 5 mCi of [3H]labeled sodium acetate per liter. The specific 
activity of the purified polysaccharide was equal to  1,200 counts per minute per microgram. 
The RABA reported by Farr (19) and modified for the detection of antibody to the group B 
streptococcal capsular polysaccharides was employed (7, 8). The percentage of antigen bound 
was related linearly to the logarithm of the antibody concentration (#g/ml) as determined by 
quantitative precipitin tests on five selected human sera. Using the method of least squares, the 
concentration of antibody could be determined from percentage of binding (20)  (r  =  0.97, 
slope =  0.0147, intercept  =  0.101). 
The opsonophagocytic assay described by Baltimore et al. was used (16). In this test bacteria, 
human polymorphonuclear leukocytes, antibody-free human complement, and patient serum 
are mixed by end over end rotation. Greater than 90% reduction of colony-forming units (cfu) 
in  1 h  is  considered significant opsonization. The  titer of serum  is  the  highest  dilution of 
antiserum which causes >90% reduction of cfu in  1 h. 
Antibody to pneumococcal polysaccharide types I, III, VIA, VII, XIV, XVIII c  (Danish 
nomenclature),  were  measured  by  using  the  radioimmunoassay method  of Schiffman  and 
Austrian (21) and are expressed as nanograms of antibody nitrogen/ml. 
Statistical Methodsl  Differences in antibody levels between groups were compared using the 
Mann-Whitney U test (22) because of the nonparametric distribution of the data. The method 
of least squares was used to relate the rise in opsonic titer (expressed in log2) and rise in antibody 
concentration  to both  the native and  core polysaccharides. The  relative significance of the 
correlation coefficients between antibody to these two antigens and opsonins was tested by Z 
transformation  (23).  The significance of differences in antibody levels within paired sera of 
groups  was  estimated  with  the  paired  t  test  (24)  which  is  employed  for  analysis of these 330  GROUP  B  STREPTOCOCCAL  IMMUNITY 
Fro.  1.  Immunodiffusion in agar of type XIV polysaeeharide of S. pneumoniae (ew) with rabbit 
antisera prepared to group B variant strain (090R)  (1), type Ia strain 090 (2), type Ib strain H36B 
(3), type Ic strain A909 (4), type II strain 18RS21  (5), and type III strain D!.36C  (6). 
nonparametrically distributed data.  For pneumococcal  antibody studies the rise in geometric 
mean titer is also given so that comparison to previously published data could be made (21). 
Results 
Immunological Definition  of the Specific Relationship  between the  Type  XIV Pneumococcal 
Capsule and  Type  III Group B  Streptococcal Antigens.  The  immunological relationship 
between the pneumococcal type XIV antigen and various type III group B strepto- 
coccal antigens was studied in agar gel diffusion. The pneumococcal XIV  antigen 
formed an immunoprecipitin with antiserum prepared to Type III group B strepto- 
cocci, but not with that prepared to group B serotype Ia, Ib, Ic, or II strains (Fig.  1). 
When pneumococcal XIV antigen and type III core polysaccharide (0% sialic acid) 
were reacted with type III group B streptocccal rabbit  antiserum, a  line of identity 
was observed  (Fig.  2).  However the immunoprecipitins formed with either of these 
two immunologically identical antigens formed partial identities with the immuno- 
preeipitin  resulting from the  reaction of native type III  (23% sialic acid)  or TCA- 
extracted  (9.6%  sialic  acid)  type  III  antigens  and  this  same  antiserum.  Identical 
precipitins were formed by the reactions of the native type III antigen and the TCA 
antigen with type III group B streptococcal antiserum (Fig. 2). 
When pneumococcal type XIV and the core type III group B streptococcal antigens 
were reacted with pneumococcal type XIV antiserum, a line of identity was seen (Fig. 
3). The TCA extracted type III group B streptococcal antigen also reacted with the 
pneumococcal  XIV  antiserum  to  give  a  line  of  identity  with  the  previous  two 
precipitins  (Fig. 3).  However, the native type III group B streptococcal antigen did 
not form immunoprecipitins with the pneumococcal XIV antiserum. 
Antibody  Levels  to  the  Core and  Native  Antigens  in  Natural  Infection.  The  acute  and D.  L.  KASPER  ET  AL.  331 
FIc.  2.  Immunodiffusion  in agar of type XIV capsular polysaccharide of S.  pneumoniae (1), core 
capsular antigen  of type III group  B Streptococcus (M732) (2), TCA extracted capsular antigen  of 
type III group B Streptococcus (M732) (3), and native capsular antigen of type III group B Streptococcus 
(M732) (4) with rabbit antiserum prepared to type III strain, M735, of group B Streptococcus. (Center 
well). 
Fie.  3.  Immunodiffusion  in agar of type XIV capsular antigen ofS. pneumoniae (l), core capsular 
antigen  of type III group  B Streptococcus (M732) (2), TCA-capsular antigen  of type III group  B 
Streptococcus (M732) (3), and native capsular antigen of type III group B Streptococcus (M732) (4) with 
rabbit antiserum prepared to type XIV S. pneumoniae. (center well). 
convalescent sera of 11  infants with invasive type III group B  streptococcal infection 
were studied to determine whether natural infection was more likely to result in a  rise 
in antibody concentration to the native or to the core type III group B  streptococcal 
polysaccharide antigens (Table I). Quantitative antibody concentrations in acute and 
convalescent sera from the patients were determined by radioactive antigen-binding 
assay. Only 2 of these  11  infants had a  detectable rise in antibody to the core antigen 
during convalescence (P>  0.5). Similarly, no significant rise in antibody concentration 
was  detected  to  the  pneumococcal  XIV  (P >  0.5)  or pneumococcal  III  (P >  0.05) 
polysaccharides.  In  contrast  9  of  11  infants  developed  detectable  rises  in  serum 
antibody to the native type III group B Streptococcus  polysaccharide antigen (P <  0.02, 
paired t test). Therefore, in natural type III group B streptococcal infection, the young 
host  is more  likely to  develop serum  antibody  directed against  native than  against 332  GROUP  B  STREPTOCOCCAL IMMUNITY 
TABLE  I 
Antibody Concentrations in Sera  from Infants with Invasive, Type 111, Group B 
Streptococcal Infection 
Antibody to the type III core anti- 
gen 
Antibody to the type III native anti- 
gen 
Acute  Convalescent  Acute  Convalescent 
~g/ml  tig/ml 
1  10.98  5.04  0.44  0.37 
2  2.4  2.3  0.34  0.37 
3  10.98  10.98  0.44  7.88 
4  3.48  4.12  0.34  13.0 
5  3.72  2.94  0.6  5.0 
6  14.88  14.39  0.0  36.0 
7  18.85  23.89  0.5  9.2 
8  4.04  4.04  0.38  6.7 
9  4.96  4.18  0.49  36.12 
10  2.48  3.54  0.37  3.9 
11  4.05  4.05  0.42  49.42 
Mean difference  in antibody concentration between paired sera  ±  standard error 
0.1:1:0.76 (P> 0.5). 16.01 ±  5.53 (P< 0.02). 
TABLE II 
Antibody Concentrations in Sera  from Mothers of Infants with Invasive, Type 
III Group B Streptococcal Infection 
Antibody to the type III  Antibody to the type III 
core antigen  native antigen 
I~g/ml  p.g/ml 
1  13.2  0.85 
2  8.2  2.52 
3  10.8  2.0 
4  5.4  0.58 
5  5.7  0.46 
6  4.0  0.42 
7  8.2  0.68 
8  8.2  0.55 
9  6.72  1.06 
10  5.86  1.00 
11  7.96  O. 77 
core  antigenic  determinants.  Notably,  sera  from  these  infants  and  their  mothers 
(Table  II)  had  significantly  higher levels of antibody  to  the core than  to  the  native 
antigen  (P <0.001  Mann-Whitney  U  test). 
The maternal and cord sera of 19 women and their healthy offspring were compared 
to the maternal and acute sera from women whose infants had invasive type III group 
B  streptococcal  infection for antibody  levels to  the type XIV  and  III pneumococcal 
polysaccharides.  No significant differences were found (Mann-Whitney  U  test). These 
studies  support  our  earlier observations  that  very low  antibody  levels to  the  native 
type  III  group  B  streptococcal  antigen  are  found  in  sera  from  infected  infants  and 
their mothers  (7,  8)  and  suggests  the unlikelihood  that  antibody  to  the core antigen D. L. KASPER ET AL.  333 
is protective, when considering the concentrations of this antibody which are present 
in the acute sera of infected infants and their mothers and in normal healthy controls. 
Antibody  Response to Group B  Streptococcus Type III Antigens  in Recipients  of Multivalent 
Pneumococcal Polysaccharide Vaccine.  12 volunteers who had low levels of antibody to 
the  native type III  group  B  streptococcal antigen  were given a  single  injection of 
multivalent pneumococcal polysaccharide vaccine. Antibody to types I, III, Via, VII, 
XIV, and XVIIIc pneumococcal polysaccharides were measured in the paired sera of 
these volunteers. Data were analyzed by three methods. Using the criterion of Fikrig 
et al.  (25)  that  a  >40%  increase between paired serum samples  is significant, 9/12 
volunteers responded to pneumococcal types I and III,  11/12 responded to type Via, 
12/12 responded to type VII, 8/12 responded to type XIV and  11/12 responded to 
type XVIIc. The rise in geometric mean titer for each polysaccharide was 3.83 (type 
1),  11.95  (type III), 8.0 (type Via),  16.9  (type VII), 2.55  (type XIV), and 6.69 (type 
XVIIIc).  Utilizing  the  paired  t  test,  the  mean  differences between  pre-  and  post- 
immunization sera for each pneumococcal type (+  standard error) were 855.26  + 
363.9 (type I), 1,321.2 ±  352.87 (type III), 211.2 +  54.16 (type Via), 563.37 +  133.47 
(type VII),  295  ±  238.43  (type XIV),  and  1,463.06  +  495.80  (type XVIIIc).  As 
analyzed by this latter method, the antibody response to the pneumococcal vaccine 
recipients was significant for type I  (P <  0.05), and types III, Via, VII, or XVIIIc, 
(P <  0.01). This group of vaccine recipients did not have a significant rise to the type 
XIV pneumococcal polysaccharide by using the paired t test for data analysis. 
Despite the  fact that  when analyzed as  a  group by the paired  t  test  the overall 
change in antibody concentration to pneumococcus XIV antigen was not significant, 
8 of the  12 individual recipients responded with over a twofold increase in antibody 
concentration, and these responders had a  rise in geometric mean titer of 3.92 fold. 
Therefore,  there  were  enough  high-level  responders  to  type  XIV  pneumococcal 
polysaccharide  upon  which  to  base  further  analysis  of the  immunodeterminant 
specificity of group B streptococcal antibodies. 
Antibodies  to the type III  group B  streptococcal core and  native polysaccharide 
antigens were quantitated in these vaccine recipients before and 2 wk after immuni- 
zation  by means  of the  RABA  (Table III).  In  the  preimmunization  sera  of these 
volunteers, as in the mothers of infected infants, significantly h!gher concentrations of 
antibody were detected to the core antigen than to the native antigens  (P <  0.001 
Mann-Whitney  U  test).  This  indicates  that  different  populations  of antibody  are 
reacting with the core and the native antigens. The geometric mean rise in antibody 
concentration to the core antigen  in  postimmunization  sera from these  12 subjects 
was  3.2  /~g/ml  and  9  had  >1  /~g/ml  increase  in  antibody  concentration.  As  was 
demonstrated in the pneumococcal XIV antibody assay, the overall rise in antibody 
concentration to the core antigen of this group was not significant using the paired t 
test (P <  0.1), however, there was a significant antibody response to the core antigen 
in  nine  of these  pneumococcal  vaccine  recipients  (P  <  0.05  paired  t  test).  The 
geometric mean increase in antibody concentration to the native antigen in postim- 
munization sera from these same individuals was 0.99/~g/ml,  and  only three dem- 
onstrated > 1/lg/ml increases (P >  0.1, paired t test). Pneumococcal vaccine induced 
significantly greater responses to the core than to the native type III antigen  (P < 
0.01  Mann-Whitney U  test) and was significantly less effective in inducing antibody 
to the native antigen than was the native type III group B streptococcal polysaccha- 334  GROUP  B STREPTOCOCCAL  IMMUNITY 
TABLE III 
Antibody Levels in Sera of Adult  Volunteers Immunized with Multivalent 
Pneumococcal Vaccine 
Antibody to type III  Antibody to type III  Type III group B Strepto- 
group B streptococcal core  group B streptococcal ha- 
antigen  tive antigen  coccus opsonic titer 
Weeks  postimmunization 
0  2  0  2  0  2 
23.5  47.95  1.63  13.58  <1:2  <1:2 
9.43  10.44  0.47  0.52  < 1:2  < 1:2 
11.17  13.88  2.26  3.68  <1:2  <1:2 
26.09  58.75  8.8  38.4  < 1:2  1:5 
14.15  10.44  3.9  3.9  <1:2  <1:2 
7.97  9.76  0.49  0.49  <1:2  <1:2 
8.81  5.88  0.42  0.52  <1:2  <1:2 
11.55  11.17  0.42  0.49  <l:2  <1:2 
15.14  26.00  0.58  0.55  <1:2  <1:2 
19.18  30.9  0.68  1.12  <1:2  <1:2 
11.95  13.68  0.52  0.47  <1:2  <1:2 
9.43  11.17  0.49  0.49  <1:2  <1:2 
Mean difference in antibody concentration  between paired sera :t: standard error 
6.80 :t: 3.26 (P< 0.1). 3.63 +  2.55 (P> 0.1). 
ride. The geometric mean rise in  11  recipients of native type III polysaccharide was 
9.86/~g/ml, and 8 demonstrated >  1 ~g/ml increase in antibody in postimmunization 
sera (P<  0.01)  (9). 
Antigenic Specificity  of Human  Opsonic  Antibodies  to  Type III Group  B  Streptococcus.  To 
determine whether antibody directed against the core or the native type III polysac- 
charide  antigens  was  more  important  in  opsonic  immunity  to  type  III  group  B 
Streptococcus,  the pre- and postimmunization sera of nine subjects developing opsonins 
who  received the  native  (EDTA)  or TCA-extracted type III group  B  streptococcal 
vaccine  and  the  one  multivalent  pneumococcal  vaccine  recipient  who  developed 
opsonins were studied. The antibody levels to the native antigen of the individuals of 
this group  who received EDTA  or TCA  vaccines have been  reported elsewhere  (9). 
Opsonic titer and quantitative antibody concentrations to the core and native antigens 
in sera from these volunteers are summarized in Table IV. All subjects were selected 
because  they  had  low  levels of antibody  to  the  native antigen  and  lacked type III 
opsonic  activity  in  their  preimmunization  sera.  These  sera  as  well  as  those  from 
mothers of infants with  invasive infection contained much  higher levels of antibody 
to the core than  to the native antigen  (P <  0.001  Mann-Whitney U  test).  Immuni- 
zation with the sialic acid containing antigens elicited a  significant rise in antibody 
concentration to both the core antigen (P <  0.05)  and the native antigen (P <  0.02, 
paired t test). However, the rise in opsonic antibody titer (log2) correlated much better 
(P <  0.001,  Z  transformation)  with the rise in antibody concentration to the native 
antigen (r =-  0.94, r 2 =  0.88)  than with the rise in antibody concentration to the core 
antigen  (r  =  0.51,  r  z  =  0.26).  These  opsonic  titers  were  similar in  tests with  two 
strains  of  type  III  group  B  Streptococcus.  Notably,  the  one  pneumococcal  vaccine 
recipient  who  developed  a  rise  in  opsonic  antibody  after  immunization  had  high 
concentration  of antibody to  the  native antigen  as well as the  core antigen.  These 
findings indicate that opsonic antibodies to type III group B  Streptococcus  are usually D.  L.  KASPER  ET  AL.  335 
TABLE  IV 
Antibody Levels in Sera  from Adult Volunteers Immunized with Type III Group B Streptococcal Vaccine 
Antibody to type III  Antibody to type III 
Vaccine given  group B streptococcal  group B streptococcal  Type III group B Strep- 
core antigen  native antigen  tococcus opsonic titer 
ttg/ral  #g/ml  lag~rat 
weeks post immunization 
0  2  0  2  0  2 
EDTA  34.2  69.6  1.31  198.0  <1:2  1:80 
EDTA  15.1  15.1  1.91  4.58  <1:2  1:2 
TCA  11.5  11.5  0.65  2.8  <1:2  1:2 
TCA  7.4  27.8  1.63  314.0  < 1:2  1:80 
EDTA  49.5  53.05  2.96  172.2  < 1:2  1:20 
EDTA  11.2  12.78  .72  33.8  <1:2  1:5 
EDTA  21.96  44.8  1.31  51.5  <1:2  1:10 
EDTA  34.2  69.6  1.46  167.0  < 1:2  1:40 
EDTA  9.1  9.1  .58  38.1  < 1  :  2  1  :  2 
Mean difference in antibody concentration between paired sera standard error. 
13.24  +  5.11 (P< 0.05).  107.71  +  35.92  (P< 0.02). 
directed against the acid-labile determinant of the native antigen and not against the 
core antigen. 
Discussion 
Although  it  seemed reasonable on  an  intuitive  basis  that  native polysaccharide 
antigens of group B Streptococcus containing complete immunodeterminants from the 
bacterial  cell surface would  be best  suited  for candidate  vaccines, no proof of the 
hypothesis had been given (6). In this study, various antigens have been compared for 
their potential ability to induce protective antibodies to type III group B Streptococcus. 
Chemically, each polysaccharide contains galactose, glucose, and  glucosamine  (9:1: 
1).  The  type  XIV  pneumococcal  capsule  and  the  core  of the  type  III,  group  B 
streptococcal capsule are identical in chemical composition and have a trisaccharide 
backbone of each of these monosaccharides and an additional terminal galactose, ~1- 
4 linked to the glucosamine of the trisaccharide (3,  12).  1 Antibodies to the type XIV 
pneumococcal  capsule  and  the  core  type  III  group  B  streptococcal  antigen  are 
identical.  The native type III antigen differs by having a  terminal sialic acid  (23% 
composition) attached to each galactose end group of the core. 1 These differences in 
chemical  structure  could  explain  the  immunologic  differences  noted  among  the 
various  antigens.  The  type  XIV  pneumococcal  capsule,  core  type  III  group  B 
streptococcal antigen, TCA extracted type III antigen, and the native type III group 
B  streptococcal capsule all  reacted with  type III  group  B  streptococcal antiserum. 
However, the reaction of identity by type III antiserum with the pneumococcal XIV 
or core type III antigen  is not complete with the precipitate between the native or 
TCA-extracted antigens and this serum. Because all four antigens share a chemically 
similar core, this structure contains  the common determinant demonstrated  by the 
reactions of these antigens with type III group B streptococcal antiserum. The presence 
of terminal sialic acid residues in the native type III group B streptococcal antigen 
(23%  sialic acid)  which  are  partially destroyed by TCA  extraction  (TCA antigen, 
9.6% sialic acid)  provide a  more complete antigenic site to precipitate antibodies in 336  GROUP  B STREPTOCOCCAL IMMUNITY 
type III antiserum which are directed against this determinant. Moreover, the presence 
of terminal  sialic  acid  residues  in  the  native  antigen  could  likely  mask  the  core 
antigenic  site,  thus  preventing  precipitation  of  this  antigen  with  the  type  XIV 
pneumococcal antiserum  which  only contains  antibodies  to the core determinants. 
The presence of fewer sialic acid residues in the TCA antigen provides an ineffective 
mask; therefore, core sites are exposed and a precipitin reaction occurs with type XIV 
pneumococcal antiserum. The core type III group B streptococcal antigen,  the type 
XIV pneumococcal capsule, and the TCA type III group B streptococcal antigen give 
identity reactions with type XIV pneumococcal antiserum. 
The chemical differences among the various antigens are directly relevant to their 
application as vaccines. Immunization of 12 healthy adults selected for low levels of 
antibody to the native type III Group B streptococcal polysaccharides with multiva- 
lent pneumococcal vaccine resulted  in significant responses to types I, III, Via, VII, 
and XVIIIc pneumococcal polysaccharides. Interestingly, the response of this group 
of normal adults  to the pneumococcal XIV capsule was not  statistically significant 
using  the  paired  t  test  for  data  analysis.  Nonetheless,  8  of  these  12  individuals 
responded to the type XIV polysaccharide with over twofold rises.  The overall rise in 
geometric  mean  titer  of this  group  of  12  adults  is  comparable  to  data  published 
elsewhere  (26,  27)  using the same assay for pneumococcal antibodies  as is reported 
here.  The  antibody  rise  in  those  eight  individuals  responding  to  the  type  XIV 
polysaccharide is of sufficient magnitude  for analyses to determine whether human 
antibody induced to the pneumococcal XIV polysaccharide offers a  feasible alterna- 
tive to immunization with native group B streptococcal polysaccharide vaccines as a 
means of preventing type III group B streptococcal disease. 
Immunization  with  multivalent  pneumococcal,vaccine  resulted  in  an  antibody 
response to the core type III group B streptococcal polysaccharide in nine of the  12 
recipients, yet only one developed a significant rise in opsonic titers to type III group 
B streptococci. Immunization with native type III antigen or TCA group B strepto- 
coccal  antigen  resulted  in  a  rise  in  antibody  to  the  more complete native group  B 
streptococcal polysaccharide in addition to the core. This finding is significant because 
the development of opsonic antibody and natural  immunity to group B Streptococcus 
is correlated with the presence of antibody to the native, rather than the core antigen. 
Sera from volunteers immunized with type III group B streptococcal or pneumo- 
coccal polysaccharide vaccines who developed opsonic antibody demonstrated a very 
significant  correlation  (r  --  0.94,  r  2  =  0.88)  between  rise in serum antibody to the 
native antigen and opsonic titers, but a  significantly poorer correlation between rise 
in antibody to the core antigen and opsonic titers to type III group B streptococci (r 
~-  0.51, r  2  --  0.25)  (P  ~  <  0.001).  All vaccine recipients were selected for immuni- 
zation  because  their  sera  contained  low  levels  of antibody  to  the  native  antigen. 
Interestingly, these vaccinees were found to have high levels of antibody to the core 
polysaccharide in their preimmunization sera. This observation may be explained by 
the  age-related acquisition  of antibody to  type XIV pneumococcal polysaccharide. 
In  natural  type III group  streptococcal  human  infection,  low  levels of maternal 
antibody  to  the  native  antigen  has  been  shown  to  be  a  significant  risk  factor  for 
development of disease in infants (7, 8). This association is lacking for antibody to the 
core structure since both infants with invasive, type III group B streptococcal disease 
and their mothers had significantly higher levels of serum antibody to the core than D.  L.  KASPER ET AL.  337 
to the native type III group B streptococcal antigen. Furthermore, maternal and cord 
sera of infants infected with  type III group B streptococci did not  differ from age- 
matched controls with respect to anti-pneumococcal XIV capsular antibodies.  The 
discrepancy between anti-core and anti-native antibody levels emphasizes the impor- 
tance of low levels of antibody to the  native type III antigen  as a  determinant  of 
susceptibility in human  infection, and  explains the findings reported by Wilkinson 
(10)  that high antibody levels to acid-extracted antigens are not infrequently found 
in acute sera of infants with group B streptococcal infection and their mothers. 
The finding that immunization of adults with native type III group B streptococcal 
polysaccharide stimulates antibody directed against  the core type III antigen might 
possibly  be  explained  by  degradation  of the  native  antigen  in  vivo  resulting  in 
exposure of its core components.  This hypothesis does not  explain our observation 
that three adults immunized with pneumococcal XIV antigen developed antibody to 
the native antigen  in their sera.  It is conceivable that  both these findings could be 
best  explained  by  the  hypothesis  of original  antigenic  sin  in  which  a  secondary 
response to an immunogen not quite identical to the primary antigen is believed to 
occur (28). 
These data confirm the importance of antibody directed against  native type III 
capsular antigen in human  immunity to type III group B Streptococcus and suggests 
that future investigations regarding human immunity to, or vaccine preparation for 
prevention of group B streptococcal disease must be based upon type-specific antigens 
containing native determinants. 
Summary 
The type III polysaccharides of group B Streptococcus in its native state chemically 
consists of glucose, galactose, glucosamine, and sialic acid. The core of this polysac- 
charide  lacks sialic acid and  precipitates  with  type III antiserum  to give a  partial 
identity with  the precipitate between the native antigen  and  this serum.  The core 
determinant is immunochemically similar to the capsular polysaccharide of type XIV 
Streptococcus pneumoniae, while the native type III group B streptococcal polysaccharide 
does not  cross-react with  type XIV  pneumococcal antiserum.  In  human  sera,  it  is 
antibody directed to the  native antigen  which  correlates very highly with  opsonic 
immunity (r  =  0.94) while a  poorer correlation exists between antibody to the core 
antigen and opsonins (r =  0.51 P <  0.001). In natural infections, an association exists 
between low levels of maternal antibody to the native antigen and risk of disease in 
the infant. This association is not true for antibody to the core structure, where both 
infected infants and their mothers have much higher levels of antibody to the core 
than the native antigens. Infected infants are also more likely to respond to infection 
by  developing  antibody  to  the  native  antigen.  Immunization  of  12  adults  with 
multivalent pneumococcal polysaccharide induced significantly better antibody re- 
sponse  to  the  core antigen  than  to  the  native,  and  this  vaccine induced  opsonic 
activity in only one recipient. Immunization of adults with type III group B strepto- 
coccal antigens  induced antibody to the native determinant  which correlated with 
opsonic  activity.  Therefore,  it  would  appear  that  native  group  B  streptococcal 
polysaccharides will provide the best candidate antigens for immunization. 
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